Answers are grounded in this paper and cite their sources.
Case report demonstrates successful implantable RVAD use for end-stage right heart failure, suggesting benefits for transplant candidates.
Severe right heart failure is typically managed using external right ventricular assist devices (RVADs) or inotropic agents while awaiting heart transplantation. Here, we report a successful case using an implantable RVAD to treat end-stage right-sided heart failure caused by arrhythmogenic right ventricular cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Miyoshi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: